These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9156656)

  • 21. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
    Sommer W; Heilig M
    Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense approaches to cancer gene therapy.
    Mercola D; Cohen JS
    Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
    Stein CA; Cheng YC
    Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
    Chen HX
    Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
    [No Abstract]   [Full Text] [Related]  

  • 26. Ex vivo bone marrow purging with oligonucleotides.
    Bergan RC
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):251-5. PubMed ID: 9212920
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines.
    Hazan-Halevy I; Landesman-Milo D; Rosenblum D; Mizrahy S; Ng BD; Peer D
    J Control Release; 2016 Dec; 244(Pt B):149-156. PubMed ID: 27491881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
    Tolcher AW
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleic acid therapeutics: state of the art and future prospects.
    Gewirtz AM; Sokol DL; Ratajczak MZ
    Blood; 1998 Aug; 92(3):712-36. PubMed ID: 9680338
    [No Abstract]   [Full Text] [Related]  

  • 31. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNAs in hematological malignancies: a novel approach to targeted therapy.
    Joshi D; Gosh K; Vundinti BR
    Hematology; 2012 May; 17(3):170-5. PubMed ID: 22664117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense regulation of oncogenes in human cancer.
    Mukhopadhyay T; Roth JA
    Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent status of the antisense oligonucleotide approaches in oncology.
    Ma L; Calvo F
    Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G-quadruplex structure at intron 2 of TFE3 and its role in Xp11.2 translocation and splicing.
    Verma SP; Das P
    Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):630-636. PubMed ID: 29138008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense oligonucleotides for cancer therapy-an overview.
    Stahel RA; Zangemeister-Wittke U
    Lung Cancer; 2003 Aug; 41 Suppl 1():S81-8. PubMed ID: 12867066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of epigenetic changes in hematological malignancies.
    Lehmann U; Brakensiek K; Kreipe H
    Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of P210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences.
    Lewalle P; Martiat P
    Leuk Lymphoma; 1993; 11 Suppl 1():139-43. PubMed ID: 8251887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting TdT gene expression in Molt-4 cells by PNA-octaarginine conjugates.
    Montazersaheb S; Avci ÇB; Bagca BG; Ay NPO; Tarhriz V; Nielsen PE; Charoudeh HN; Hejazi MS
    Int J Biol Macromol; 2020 Dec; 164():4583-4590. PubMed ID: 32941907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.